Analysis of SARS-CoV-2 Spike Protein as The Key Target in the Development of Antiviral Candidates for COVID-19 through Computational Study

T. M. Fakih, Mentari Luthfika Dewi
{"title":"Analysis of SARS-CoV-2 Spike Protein as The Key Target in the Development of Antiviral Candidates for COVID-19 through Computational Study","authors":"T. M. Fakih, Mentari Luthfika Dewi","doi":"10.25026/jtpc.v5i4.254","DOIUrl":null,"url":null,"abstract":"The recent public health crisis is threatening the world with the emergence of the spread of the new coronavirus 2019 (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus originates from bats and is transmitted to humans through unknown intermediate animals in Wuhan, China in December 2019. Advances in technology have opened opportunities to find candidates for natural compounds capable of preventing and controlling COVID-19 infection through inhibition of spike proteins of SARS-CoV-2. This research aims to identify, evaluate, and explore the structure of spike protein macromolecules from three coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) and their effects on Angiotensin-Converting Enzyme 2 (ACE-2) using computational studies. Based on the identification of the three spike protein macromolecules, it was found that there was a similarity between the active binding sites of ACE-2. These observations were then confirmed using a protein-docking simulation to observe the interaction of the protein spike to the active site of ACE-2. SARS-COV-2 spike protein has the strongest bond to ACE-2, with an ACE score of −1341.85 kJ/mol. Therefore, some of this information from the results of this research can be used as a reference in the development of competitive inhibitor candidates for SARS-CoV-2 spike proteins for the treatment of COVID-19 infectious diseases.","PeriodicalId":17494,"journal":{"name":"Journal of Tropical Pharmacy and Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Tropical Pharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25026/jtpc.v5i4.254","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The recent public health crisis is threatening the world with the emergence of the spread of the new coronavirus 2019 (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus originates from bats and is transmitted to humans through unknown intermediate animals in Wuhan, China in December 2019. Advances in technology have opened opportunities to find candidates for natural compounds capable of preventing and controlling COVID-19 infection through inhibition of spike proteins of SARS-CoV-2. This research aims to identify, evaluate, and explore the structure of spike protein macromolecules from three coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) and their effects on Angiotensin-Converting Enzyme 2 (ACE-2) using computational studies. Based on the identification of the three spike protein macromolecules, it was found that there was a similarity between the active binding sites of ACE-2. These observations were then confirmed using a protein-docking simulation to observe the interaction of the protein spike to the active site of ACE-2. SARS-COV-2 spike protein has the strongest bond to ACE-2, with an ACE score of −1341.85 kJ/mol. Therefore, some of this information from the results of this research can be used as a reference in the development of competitive inhibitor candidates for SARS-CoV-2 spike proteins for the treatment of COVID-19 infectious diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过计算研究分析SARS-CoV-2刺突蛋白作为新冠病毒候选抗病毒药物开发的关键靶点
随着新型冠状病毒2019 (2019- ncov)或严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)的出现,最近的公共卫生危机正在威胁世界。该病毒起源于蝙蝠,于2019年12月在中国武汉通过未知中间动物传播给人类。技术的进步为寻找能够通过抑制SARS-CoV-2刺突蛋白来预防和控制COVID-19感染的天然化合物的候选物提供了机会。本研究旨在利用计算方法鉴定、评估和探索三种冠状病毒(SARS-CoV、MERS-CoV和SARS-CoV-2)刺突蛋白大分子的结构及其对血管紧张素转换酶2 (ACE-2)的影响。通过对三个刺突蛋白大分子的鉴定,发现ACE-2的活性结合位点具有相似性。这些观察结果随后通过蛋白质对接模拟得到证实,以观察蛋白质刺突与ACE-2活性位点的相互作用。SARS-COV-2刺突蛋白与ACE-2结合最强,ACE评分为−1341.85 kJ/mol。因此,本研究结果的部分信息可作为开发SARS-CoV-2刺突蛋白竞争性抑制剂候选物以治疗COVID-19传染病的参考。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
12
审稿时长
6 weeks
期刊最新文献
Evaluation of the Knowledge, Attitude and Perception of Healthcare Students on Antibiotics and Antibiotic Resistance: A Study in Central University, Ghana Test of Antidiabetic Effect of Taro Leaf Extract (Colocasia esculenta L.) on Zebrafish (Danio rerio) Flavonoid Level Determination in Jamu Pegel Linu in Magelang Regency Using Uv-Visible Spectrophotometry Evaluation of the Suitability of Using Anticholesterol Drugs in Cholesterol Patients at Sekip Public Health Centre Palembang Isolation and Cytotoxic Activity Test of Alkaloids from Dichloromethane Fraction of Bark of Tampa Badak (Voacanga foetida (Blume) Rolfe) Against T47D Cell Line
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1